FIELD: medicine.
SUBSTANCE: invention relates to medicine and is intended for the treatment of fatty liver disease. 15-hydroxy-eicosapentaenoic acid is used in the form of a free acid, 15-hydroxy-eicosa-5,8,11,13,17-pentaenoic acid and/or a pharmaceutically acceptable ester, conjugate or salt or mixtures thereof.
EFFECT: invention widens the range of therapeutic agents.
11 cl, 4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING 15-HEPE, AND METHODS OF TREATING OR PREVENTING FIBROSIS USING SAID COMPOSITIONS | 2015 |
|
RU2721555C2 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
| NEW APPLICATIONS AND METHODS | 2017 |
|
RU2765804C2 |
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
| KIT FOR PREDICTION OR DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE AND A METHOD OF DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2020 |
|
RU2800086C1 |
| PREVENTIVE AND THERAPEUTIC DRUG FOR NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2820552C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN FEMALES | 2020 |
|
RU2744021C1 |
